The market for preserving cells and tissue is growing rapidly and is diverging into new technology areas, one of which is vitrification, or freezing rapidly to avoid the presence of ice crystals.
The issuance of the patent provides BioLife with the latest extension of its molecular-based cryopreservation technology platform and protects BioLife’s use of cell death inhibitors (calpain inhibitors) in hypothermic preservation solutions.
“Our core preservation technologies can be a critical factor in applying this new technology and solidifying our patent position in that area gives us a commercial foothold as that market develops,” commentedB ioLife president and CEO, Dr John Baust.
“We believe BioLife holds a unique and encompassing intellectual property position in the biological processing and preservation of cells, tissues and organs and that our technology significantly improves the viability of cells and organs for longer periods of time during transportation and storage,” added Dr Baust.